Sutro Biopharma (STRO) Other Non Operating Income (2017 - 2018)
Sutro Biopharma recorded quarterly Other Non Operating Income of $1.1 million in Q4 2018, up 1677.94% quarter-over-quarter from -$68000.0 in Q3 2018, and up 794.17% year-over-year from $120000.0 in Q4 2017.
Sutro Biopharma's Other Non Operating Income history runs 2 years deep, the most recent figure standing at $1.1 million for Q4 2018.
- In Q4 2018, Other Non Operating Income rose 794.17% year-over-year to $1.1 million; the TTM figure through Dec 2018 stood at $945000.0 (changed N/A YoY), while the FY2018 annual figure was $1.9 million, up 2584.42% from the prior year.
- Other Non Operating Income came in at $1.1 million for Q4 2018 at Sutro Biopharma, up from -$68000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.1 million in Q4 2018 to a low of -$180000.0 in Q3 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Sutro Biopharma | 248.39 Mn | 248.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.07 Mn |
| Sep 30, 2018 | -68,000.00 |
| Dec 31, 2017 | 120,000.00 |
| Sep 30, 2017 | -180,000.00 |